| Cash Flow | 2025-08-31 |
|---|---|
| Net loss | -186,236 |
| Depreciation and amortization | 6,620 |
| Stock-based compensation | 28,879 |
| Net accretion of discount on marketable securities | 8,455 |
| Amortization of operating lease right-of-use assets | 7,605 |
| Other | 0 |
| Prepaid expenses and other assets | 4,945 |
| Accounts payable | -3,655 |
| Deferred revenue | -23,403 |
| Operating lease liabilities | -4,311 |
| Accrued expenses and other current liabilities | 6,268 |
| Net cash used in operating activities | -181,633 |
| Purchases of marketable securities | 281,350 |
| Maturities of marketable securities | 437,728 |
| Purchases of property and equipment | 8,871 |
| Net cash provided by (used in) investing activities | 147,507 |
| Proceeds from exercise of stock options | 405 |
| Proceeds from issuance of common stock under employee stock purchase plan | 2,229 |
| Proceeds from issuances of common stock and pre-funded warrants in equity financing, net of issuance costs | 0 |
| Proceeds from issuances of common stock in at the market financing, net of issuance costs | 0 |
| Repurchase of unvested early exercised stock options | 0 |
| Net cash provided by financing activities | 2,634 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -31,492 |
| Cash and cash equivalents at beginning of period | 110,898 |
| Cash and cash equivalents at end of period | 79,406 |
Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX)